Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 1 patch per pouch (NDC 66758-208-58), pa...
FDA Drug Recall #D-0481-2017 — Class II — February 2, 2017
Recall Summary
| Recall Number | D-0481-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | February 2, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sandoz Inc |
| Location | Princeton, NJ |
| Product Type | Drugs |
| Quantity | 157,922 cartons |
Product Description
Transderm Scop (scopolamine) Transdermal System, 1.5 mg, 1 patch per pouch (NDC 66758-208-58), packaged in 4-count patches per carton (NDC 66758-208-54), Rx Only, Manufactured by ALZA Corporation, Vacaville, CA 95688 for Sandoz Inc., Princeton, NJ 08540.
Reason for Recall
Labeling: Incorrect Instructions:outer carton contains the incorrect instructions for Step 2 stating "Do cut the patch" rather than the correct instructions of "Do not cut the patch". The pouch containing the patch is labeled correctly.
Distribution Pattern
Nationwide in the USA and Puerto Rico
Lot / Code Information
Lot #: 6323Q11, 6328Q11, Exp 06/19; 6355Q11, Exp 07/19
Other Recalls from Sandoz Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0651-2025 | Class II | Cyclophosphamide Injection 500 mg/5 mL (100 mg/... | Sep 5, 2025 |
| D-0626-2025 | Class II | Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic ... | Aug 13, 2025 |
| D-0569-2025 | Class I | Cefazolin for Injection, USP, 1 gram per vial, ... | Jun 27, 2025 |
| D-0570-2025 | Class I | Buffered Penicillin G Potassium for Injection, ... | Jun 27, 2025 |
| D-0286-2022 | Class I | Enoxaparin Sodium Injection, USP, 40 mg/0.4 mL,... | Nov 17, 2021 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.